New cancer vaccine targets 'Undruggable' KRAS mutations in early trial
Disease control
Completed
This early-stage trial tested a new immunotherapy called ELI-002 in 25 people with pancreatic, colorectal, lung, and other cancers that have specific KRAS mutations. The treatment was given after standard therapy to target any remaining cancer cells and prevent recurrence. Resear…
Phase: PHASE1 • Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC